A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma: Part II: Treatment Success and Globe Salvage.


Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
12 2020
Historique:
received: 20 04 2020
revised: 28 05 2020
accepted: 29 05 2020
pubmed: 12 6 2020
medline: 27 2 2021
entrez: 12 6 2020
Statut: ppublish

Résumé

To evaluate the ability of the American Joint Committee on Cancer (AJCC) 8th edition to predict local tumor control and globe salvage for children with retinoblastoma (RB). International, multicenter, registry-based retrospective case series. A total of 2854 eyes of 2097 patients from 18 ophthalmic oncology centers from 13 countries over 6 continents. International, multicenter, registry-based data were pooled from patients enrolled between January 2001 and December 2013. All RB eyes with adequate records to allow tumor staging by the AJCC 8th edition criteria and follow-up to ascertain treatment outcomes were included. Globe-salvage rates were estimated by AJCC clinical (cTNMH) categories and tumor laterality. Local treatment failure was defined as use of enucleation or external beam radiation therapy (EBRT), with or without plaque brachytherapy or intra-arterial chemotherapy (IAC). Unilateral RB occurred in 1340 eyes (47%). Among the 2854 eyes, tumor categories were cT1 to cT4 in 696 eyes (24%), 1334 eyes (47%), 802 eyes (28%), and 22 eyes (1%), respectively. Of these, 1275 eyes (45%) were salvaged, and 1179 eyes (41%) and 400 eyes (14%) underwent primary and secondary enucleation, respectively. The 2- and 5-year Kaplan-Meier cumulative globe-salvage rates without the use of EBRT by cTNMH categories were 97% and 96% for category cT1a tumors, 94% and 88% for cT1b tumors, 68% and 60% for cT2a tumors, 66% and 57% for cT2b tumors, and 32% and 25% for cT3 tumors, respectively. Risk of local treatment failure increased with increasing cT category (P < 0.001). Cox proportional hazards regression analysis confirmed a higher risk of local treatment failure in categories cT1b (hazard ratio [HR], 3.5; P = 0.004), cT2a (HR, 15.1; P < 0.001), cT2b (HR, 16.4; P < 0.001), and cT3 (HR, 45.0; P < 0.001) compared with category cT1a. Use of plaque brachytherapy and IAC improved local tumor control in categories cT1a (P = 0.031) and cT1b (P < 0.001). Multicenter, international, internet-based data sharing validated the 8th edition AJCC RB staging to predict globe-salvage in a large, heterogeneous, real-world patient population with RB.

Identifiants

pubmed: 32526306
pii: S0161-6420(20)30524-8
doi: 10.1016/j.ophtha.2020.05.051
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1733-1746

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Ankit Singh Tomar (AS)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York.

Paul T Finger (PT)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York. Electronic address: pfinger@eyecancer.com.

Brenda Gallie (B)

The Eye Cancer Clinic, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Ashwin Mallipatna (A)

Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada.

Tero T Kivelä (TT)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Chengyue Zhang (C)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Junyang Zhao (J)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Matthew W Wilson (MW)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee; Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee.

Rachel C Brenna (RC)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee; Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee.

Michala Burges (M)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, Memphis, Tennessee; Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee.

Jonathan Kim (J)

USC Roski Eye Institute, Keck Medical School of the University of Southern California, Los Angeles, California The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Vikas Khetan (V)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Suganeswari Ganesan (S)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Andrey Yarovoy (A)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Vera Yarovaya (V)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Elena Kotova (E)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Yacoub A Yousef (YA)

Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan.

Kalle Nummi (K)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tatiana L Ushakova (TL)

SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation; Medical Academy of Postgraduate Education, Moscow, Russian Federation.

Olga V Yugay (OV)

SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation.

Vladimir G Polyakov (VG)

SRI of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation; Medical Academy of Postgraduate Education, Moscow, Russian Federation.

Marco A Ramirez-Ortiz (MA)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Elizabeth Esparza-Aguiar (E)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Guillermo Chantada (G)

Precision Medicine Coordination Hospital JP Garrahan, Buenos Aires, Argentina and CONICET, National Scientific and Technical Research Council, Argentina.

Paula Schaiquevich (P)

Precision Medicine Coordination Hospital JP Garrahan, Buenos Aires, Argentina and CONICET, National Scientific and Technical Research Council, Argentina.

Adriana Fandino (A)

Ophthalmology Service Hospital JP Garrahan, Buenos Aires, Argentina.

Jason C Yam (JC)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong.

Winnie W Lau (WW)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong.

Carol P Lam (CP)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Kowloon, Hong Kong.

Phillipa Sharwood (P)

Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of Sydney, Sydney, Australia.

Sonia Moorthy (S)

KK Women's and Children's Hospital, Singapore.

Quah Boon Long (QB)

KK Women's and Children's Hospital, Singapore.

Vera Adobea Essuman (VA)

Ophthalmology Unit, Department of Surgery, School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana.

Lorna A Renner (LA)

Department of Child Health, University of Ghana Medical School, Accra, Ghana.

Ekaterina Semenova (E)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York.

Jaume Català (J)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.

Genoveva Correa-Llano (G)

Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.

Elisa Carreras (E)

Retinoblastoma Unit, Department of Oncology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH